Evaluation of t-RFA and RF-TVA Prior to/Following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s)

NATerminatedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Metastatic Lesions in Vertebral Bodies
Interventions
DEVICE

STAR™ Tumor Ablation System

Targeted-radiofrequency ablation (t-RFA)

DEVICE

StabiliT® Vertebral Augmentation System

Radiofrequency-targeted vertebral augmentation (RF-TVA)

Trial Locations (14)

22304

Inova Alexandria Hospital, Alexandria

27157

Wake Forest, Winston-Salem

33612

Moffitt Cancer Center, Tampa

53226

Medical College of Wisconsin, Milwaukee

55901

Mayo Clinic, Rochester

60439

Vascular and Interventional Radiology, La Grange

60611

Northwestern University, Feinberg School of Medicine, Chicago

63110

Washington University/Siteman Cancer Center, St Louis

66160

University of Kansas Medical Center, Kansas City

84107

St. Marks Hospital, Salt Lake City

90505

Torrance Memorial Medical Center, Torrance

99204

Providence Sacred Heart, Spokane

90032-9235

USC, Los Angeles

75390-9183

University of Texas Southwestern, Dallas

Sponsors
All Listed Sponsors
collaborator

DFINE Inc.

INDUSTRY

lead

Merit Medical Systems, Inc.

INDUSTRY

NCT02225223 - Evaluation of t-RFA and RF-TVA Prior to/Following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s) | Biotech Hunter | Biotech Hunter